A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer.

Clinical Genitourinary Cancer
Nicholas SpetsierisEleni Efstathiou

Abstract

Resistance to novel androgen signaling inhibition and metastatic castration-resistant prostate cancer (mCRPC) progression is likely dependent on tumor microenvironment interactions. The Src pathway and neoangiogenesis have been implicated in prostate cancer progression. We studied the effect of adding the targeted agents dasatinib and sunitinib to abiraterone acetate (AA) in men with mCRPC. In this open-label randomized phase 2 study, mCRPC patients received AA. At resistance to AA, they were randomized 1:1 to combination with dasatinib or sunitinib. At second progression, patients crossed over. The primary end point was time to treatment failure (TTF), defined as time to progression or death. Secondary end points included overall survival and safety. From March 2011 to February 2015, a total of 179 patients were enrolled and 132 subsequently randomized. Median TTF was 5.7 months in the dasatinib group and 5.5 months in the sunitinib group. There was no difference between the two groups in terms of TTF (hazard ratio, 0.85; 95% confidence interval, 0.59-1.22). Median overall survival from study entry was 26.3 months in the dasatinib group and 27.7 months in the sunitinib group (hazard ratio, 1.02; 95% confidence interval, 0.71-1...Continue Reading

References

May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shahrokh F ShariatKevin M Slawin
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Apr 12, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K Fizazi
Mar 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard I ScherUNKNOWN Prostate Cancer Clinical Trials Working Group
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
May 1, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M Dror MichaelsonM R Smith
May 19, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Oleg TatarovJoanne Edwards
Jul 28, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G SonpavdeT E Hutson
Nov 19, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Evan Y YuCora N Sternberg
Feb 11, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eleni Efstathiou, Christopher J Logothetis
Jun 8, 2010·The New England Journal of Medicine·Hagop KantarjianMichele Baccarani
Feb 11, 2011·The New England Journal of Medicine·Eric RaymondPhilippe Ruszniewski
Aug 9, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A J ZuritaC J Logothetis
Dec 11, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Dror MichaelsonIsan Chen
Jun 3, 2014·The New England Journal of Medicine·Tomasz M BeerUNKNOWN PREVAIL Investigators
May 21, 2017·Cancer Treatment Reviews·Giuseppe GallettiScott T Tagawa
Jun 6, 2017·The New England Journal of Medicine·Nicholas D JamesUNKNOWN STAMPEDE Investigators
Mar 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A J ZuritaC J Logothetis

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.